Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acetaminophen + Caffeine (also known as paracetamol with caffeine) is an approved oral small molecule combination drug used for the relief of mild to moderate pain. The combination consists of **acetaminophen**, a non-opioid analgesic and antipyretic, and **caffeine**, a methylxanthine that acts as a central nervous system stimulant and analgesic adjuvant. Acetaminophen primarily works by inhibiting prostaglandin synthesis in the central nervous system, thereby reducing pain and fever. Caffeine acts as an adenosine receptor antagonist; in this combination, it enhances the analgesic efficacy of acetaminophen and may accelerate its onset of action by modulating pain perception and improving drug absorption. It is commonly indicated for conditions such as tension headaches, migraines, musculoskeletal pain, and general aches.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetaminophen + caffeine.